Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate (ADC) designed to treat specific cancers, including metastatic triple-negative breast cancer, by delivering the cytotoxic agent SN-38… Read more
Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate (ADC) designed to treat specific cancers, including metastatic triple-negative breast cancer, by delivering the cytotoxic agent SN-38 directly to tumor cells. This complex molecule consists of a monoclonal antibody linked to the active metabolite of irinotecan, necessitating rigorous analytical oversight during development and manufacturing. This category offers high-quality reference standards essential for characterizing the API and conducting thorough impurity profiling to ensure product safety and efficacy. Pharmaceutical laboratories utilize these materials for method validation, degradation studies, and stability testing. Additionally, the inclusion of stable isotope labelled compounds provides critical internal standards for bioanalytical quantification, allowing researchers to accurately track the pharmacokinetics of the drug and its metabolites. These specialized reagents support the maintenance of strict quality control standards throughout the lifecycle of this innovative therapeutic agent.